GUCY1A1

Chr 4AR

guanylate cyclase 1 soluble subunit alpha 1

Also known as: GC-S-alpha-1, GC-SA3, GCS-alpha-3, GUC1A3, GUCA3, GUCSA3, GUCY1A3, MYMY6

The encoded protein is the alpha subunit of soluble guanylate cyclase, which forms a heterodimeric enzyme with a beta subunit to catalyze the conversion of GTP to cyclic GMP in response to nitric oxide signaling. Biallelic mutations cause Moyamoya disease 6 with achalasia, an autosomal recessive condition affecting cerebral vasculature and esophageal motility. The gene shows moderate constraint against loss-of-function variants (LOEUF 0.84).

Summary from RefSeq, OMIM
Research Assistant →

Primary Disease Associations & Inheritance

Moyamoya 6 with achalasiaMIM #615750
AR
UniProtMoyamoya disease 6 with or without achalasia
0
Active trials
6
Pubs (1 yr)
50
P/LP submissions
2%
P/LP missense
0.84
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryGUCY1A1
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
46 unique Pathogenic / Likely Pathogenic· 103 VUS of 225 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.84LOEUF
pLI 0.000
Z-score 2.25
OE 0.56 (0.380.84)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.68Z-score
OE missense 0.90 (0.820.99)
334 obs / 370.9 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.56 (0.380.84)
00.351.4
Missense OE0.90 (0.820.99)
00.61.4
Synonymous OE1.03
01.21.6
LoF obs/exp: 17 / 30.4Missense obs/exp: 334 / 370.9Syn Z: -0.29
DN
0.6648th %ile
GOF
0.6932th %ile
LOF
0.3455th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

225 submitted variants in ClinVar

Classification Summary

Pathogenic39
Likely Pathogenic7
VUS103
Likely Benign38
Benign12
Conflicting2
39
Pathogenic
7
Likely Pathogenic
103
VUS
38
Likely Benign
12
Benign
2
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
5
1
33
0
39
Likely Pathogenic
2
0
5
0
7
VUS
1
92
9
1
103
Likely Benign
0
7
9
22
38
Benign
0
3
6
3
12
Conflicting
2
Total81036226201

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

GUCY1A1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC